EGFR and non-small cell lung carcinoma: The discovery of epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer and other types of cancers and the application of EGFR inhibitor have launched a new era of personalized medicine in patients with advanced non-small cell lung carcinoma (NSCLC) [41].